SCHEMBL6746035

SCHEMBL6746035

O=C1CC(CO)Oc2ccccc21

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.56
ADORA3 P0DMS8 3/20 0.56
AR P10275 2/20 0.56
KDM4E B2RXH2 1/20 0.56
CYP19A1 P11511 1/20 0.56
HSD17B10 Q99714 1/20 0.56
ABCB1 P08183 3/20 0.55
SIGMAR1 Q99720 3/20 0.55
NPC1 O15118 3/20 0.53
RAB9A P51151 3/20 0.53
MAPT P10636 2/20 0.53
HSD11B1 P28845 1/20 0.53
AKR1C3 P42330 1/20 0.53
CYP3A4 P08684 1/20 0.53
MAPK1 P28482 1/20 0.53
HTR1A P08908 1/20 0.51
AXL P30530 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30997908 1.00 MAOB (0.56) MAOBADORA3ARKDM4ECYP19A1
SCHEMBL6836994 0.83 ABCB1 (0.49) MAOBADORA3ARKDM4ECYP19A1
SCHEMBL6746055 0.83 MAOB (0.56) MAOBADORA3ARKDM4ECYP19A1
SCHEMBL6746044 0.83 MAOB (0.56) MAOBADORA3ARKDM4ECYP19A1
SCHEMBL6746049 0.83 MAOB (0.56) MAOBADORA3ARKDM4ECYP19A1
SCHEMBL23662356 0.83 MAOB (0.56) MAOBADORA3ARKDM4ECYP19A1
SCHEMBL6828123 0.83 MAOB (0.56) MAOBADORA3ARKDM4ECYP19A1
SCHEMBL6350221 0.82 MAOB (0.55) MAOBADORA3ARKDM4ECYP19A1
SCHEMBL7599711 0.82 ABCB1 (0.48) MAOBADORA3ARKDM4ECYP19A1
Hydrochloric Acid SCHEMBL6746169 0.81 MAOB (0.54) MAOBADORA3ARKDM4ECYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11421223-B2 Processes and host cells for genome, pathway, and biomolecular engineering ENEVOLV, INC. (US) 2022-08-23 US disclosed
US-20190309289-A1 PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING ENEVOLV, INC. 2019-10-10 US disclosed
US-10370654-B2 Processes and host cells for genome, pathway, and biomolecular engineering ENEVOLV, INC. (US) 2019-08-06 US disclosed
US-20180320170-A1 PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING ENEVOLV, INC. 2018-11-08 US disclosed
US-9944925-B2 Processes and host cells for genome, pathway, and biomolecular engineering ENEVOLV, INC. 2018-04-17 US disclosed
US-20160186168-A1 PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING ENEVOLV, INC. 2016-06-30 US disclosed
US-9119401-B2 Plant glutamine synthetase inhibitors and methods for their identification MARRONE BIO INNOVATIONS, INC. (US) 2015-09-01 US disclosed
US-20140113816-A1 PLANT GLUTAMINE SYNTHETASE INHIBITORS AND METHODS FOR THEIR IDENTIFICATION PRO FARM GROUP, INC. 2014-04-24 US disclosed
US-6756403-B2 6-AMINOCHROMAN-2-YL CARBOXYLIC ACIDS AND ESTERS AS PLATELET AGGREGATION INHIBITORS; FROM PHENOL AND KETOGLUTARIC ACID; OR FROM 2-HYDROXYACETOPHENONE AND DIETHYLOXALATE; OR FROM NITROPHENOL AND DIETHYL ESTER OF MALEIC ACID ELI LILLY AND COMPANY 2004-06-29 US disclosed
US-20040053992-A1 Methods for producing chiral chromones, chromanes, amino substituted chromanes and intermediates therefor ELI LILLY AND COMPANY 2004-03-18 US disclosed
EP-1292589-A2 METHODS FOR PRODUCING CHIRAL CHROMONES, CHROMANES, AMINO SUBSTITUTED CHROMANES AND INTERMEDIATES THEREFOR MILLENIUM PHARMACEUTICALS, INC. (US) 2003-03-19 EP disclosed
WO-2001094335-A2 METHODS FOR PRODUCING CHIRAL CHROMONES, CHROMANES, AMINO SUBSTITUTED CHROMANES AND INTERMEDIATES THEREFOR ELI LILLY & COMPANY (US) 2001-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053992-A1 Methods for producing chiral chromones, chromanes, amino substituted chromanes and intermediates therefor NOTUM, FAR1, CYP51A1 MAOB 1458/4885ADORA3 1304/4885AR 3660/4885
US-20140113816-A1 PLANT GLUTAMINE SYNTHETASE INHIBITORS AND METHODS FOR THEIR IDENTIFICATION GLUL, ASNS, GLS MAOB 396/4885ADORA3 4231/4885AR 4863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.